FDA Boss Defends Controversial Drug Approval After Major Criticism

The head of America's drug approval agency is under fire for recent decisions that have upset many in the healthcare industry.

FDA Commissioner Marty Makary is defending his agency after approving a drug from Replimune (a pharmaceutical company that makes medicines). The FDA (Food and Drug Administration - the U.S. government agency that decides which medicines are safe to sell) has faced criticism for how it's been approving new drugs.

The controversy centers around concerns that the FDA might be: • Approving drugs too quickly without enough testing • Not following its usual strict safety procedures • Facing pressure from drug companies to speed up approvals

This matters because when the FDA approves a drug, it means: • Doctors can prescribe it to patients • Insurance companies might cover the cost • The drug company can start selling it and making money

Why this affects the stock market: When the FDA approves a drug, the company's stock price (the cost to buy a share of the company) usually goes up because investors expect the company to make more money. When there's controversy, it can make investors nervous about pharmaceutical stocks.

Makary insists the FDA is following proper procedures and putting patient safety first. However, critics worry that rushing drug approvals could lead to dangerous medicines reaching patients.

This is an AI-generated summary. Read the original article at: https://www.cnbc.com/2026/05/05/fda-commissioner-marty-makary-defends-himself-under-pressure-.html